Pathogens (May 2023)

MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection

  • Janie R. Byrum,
  • Eric Waltari,
  • Owen Janson,
  • Syuan-Ming Guo,
  • Jenny Folkesson,
  • Bryant B. Chhun,
  • Joanna Vinden,
  • Ivan E. Ivanov,
  • Marcus L. Forst,
  • Hongquan Li,
  • Adam G. Larson,
  • Lena Blackmon,
  • Ziwen Liu,
  • Wesley Wu,
  • Vida Ahyong,
  • Cristina M. Tato,
  • Krista M. McCutcheon,
  • Rebecca Hoh,
  • J. Daniel Kelly,
  • Jeffrey N. Martin,
  • Michael J. Peluso,
  • Timothy J. Henrich,
  • Steven G. Deeks,
  • Manu Prakash,
  • Bryan Greenhouse,
  • Shalin B. Mehta,
  • John E. Pak

DOI
https://doi.org/10.3390/pathogens12050671
Journal volume & issue
Vol. 12, no. 5
p. 671

Abstract

Read online

A multiplexed enzyme-linked immunosorbent assay (ELISA) that simultaneously measures antibody binding to multiple antigens can extend the impact of serosurveillance studies, particularly if the assay approaches the simplicity, robustness, and accuracy of a conventional single-antigen ELISA. Here, we report on the development of multiSero, an open-source multiplex ELISA platform for measuring antibody responses to viral infection. Our assay consists of three parts: (1) an ELISA against an array of proteins in a 96-well format; (2) automated imaging of each well of the ELISA array using an open-source plate reader; and (3) automated measurement of optical densities for each protein within the array using an open-source analysis pipeline. We validated the platform by comparing antibody binding to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antigens in 217 human sera samples, showing high sensitivity (0.978), specificity (0.977), positive predictive value (0.978), and negative predictive value (0.977) for classifying seropositivity, a high correlation of multiSero determined antibody titers with commercially available SARS-CoV-2 antibody tests, and antigen-specific changes in antibody titer dynamics upon vaccination. The open-source format and accessibility of our multiSero platform can contribute to the adoption of multiplexed ELISA arrays for serosurveillance studies, for SARS-CoV-2 and other pathogens of significance.

Keywords